Figure 1 (Increlex 01)
Increlex Injection
Product Images NDC 71863-216
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Increlex (NDC 71863-216). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Eton Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (Increlex 02)
This description is not available.*
Image (Increlex 03)
Image (Increlex 04)
Image (Increlex 05)
Image (Increlex 06)
Image (Increlex 07)
Image (Increlex 08)
Image (Increlex 09)
Image (Increlex 10)
Image (Increlex 11)
Image (Increlex 12)
Image (Increlex 13)
Image (Increlex 14)
Image (Increlex 15)
Principal Display Panel (4 mL Vial Carton)
This text describes a medication called Increlex (mecasermin) injection intended for subcutaneous use only. It is supplied in a 40mg/4mL (10mg/mL) multiple-dose vial manufactured by Eton Pharmaceuticals, Inc. The product contains ingredients such as Mecasermin, Benzyl Alcohol, Glacial Acetic Acid, Polysorbate 20, Sodium Acetate, Sodium Chloride, and Water for Injection. It provides dosing and storage information, stressing refrigeration between 2-8°C (36-46 °F) and recommending use within 30 days of first opening. This medication is distributed in the USA with license number 2353 and in Germany through Barter Oncology GmbH.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
